

# 2Q 2025 Financial Results

**TOTAL REVENUE** 

\$222.9M

+7.6% VS. 2Q 2024

**ADJUSTED EBITDA** 

\$51.2M

+4.9% VS. 2Q 2024

**ADJUSTED FREE CASH FLOW** 

\$6M

YTD +35M; 35% CONVERSION OF ADJUSTED EBITDA



"Nuclear power and cancer care tailwinds remain vibrant and Mirion is better positioned than ever to capitalize on these favorable market trends. We improved our strategic positioning and operating performance while successfully minimizing our tariff exposure to date."

Thomas Logan,
Chief Executive Officer
& Chairman of the Board

### **QUARTER HIGHLIGHTS**

#### **Growing Momentum in Nuclear Power**

Opportunities increasing across new builds, installed base, and SMRs; ~80% of Nuclear Power end market revenue comes from the installed base and often come with higher margins

#### **Broadening Our Nuclear Power Portfolio**

New solutions meeting customers' evolving needs and supporting Mirion's digital innovation strategy

### **Improving Our Capital Structure**

Successfully executed a \$400 million convertible notes offering and refinanced our Term Loan B



## **2025** Financial Outlook

REVENUE GROWTH

7.0-9.0%

**ORGANIC REVENUE GROWTH** 

5.0-7.0%

**ADJUSTED EBITDA** 

\$223M-\$233M

**ADJUSTED EBITDA MARGIN** 

24.0-25.0%

**ADJUSTED FREE CASH FLOW** 

\$95M-\$115M

43-49% CONVERSION

**ADJUSTED EPS** 

\$0.48-\$0.52

Mirion announced 2Q 2025 financial results on July 31, 2025. Full results, reconciliations and forward-looking statements available in the Earnings Press Release and Earnings Presentation.